{"transactions":[{"id":731924,"issuer":{"id":4972,"kind":"organization","name":"ARDELYX, INC."},"owners":[{"id":36785,"kind":"person","name":"Bertrand William C JR","position":1,"cik":"0001291937","reported_name":"Bertrand William C JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-18T20:02:46.000Z","date":"2026-06-16","kind":"grant","planned":false,"acquired":true,"shares":39715,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date."}],"balance_after":39715,"derivative":{"exercise_price":5.67,"expiration_date":"2036-06-16","underlying":"Common Stock","underlying_shares":39715},"source":{"system":"sec-edgar","filing":"0001291937-26-000003","document":"wk-form4_1781812963.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1437402/000129193726000003/wk-form4_1781812963.xml","form_type":"4"}},{"id":731923,"issuer":{"id":4972,"kind":"organization","name":"ARDELYX, INC."},"owners":[{"id":36785,"kind":"person","name":"Bertrand William C JR","position":1,"cik":"0001291937","reported_name":"Bertrand William C JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-18T20:02:46.000Z","date":"2026-06-16","kind":"grant","planned":false,"acquired":true,"shares":26455,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Restricted stock units (\"RSUs\"). The Reporting Person is entitled to receive one (1) share of Common Stock for each one (1) RSU upon the vesting thereof. The RSUs were issued pursuant to the Issuer's Non-Employee Director Compensation Program."}],"balance_after":329507,"source":{"system":"sec-edgar","filing":"0001291937-26-000003","document":"wk-form4_1781812963.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1437402/000129193726000003/wk-form4_1781812963.xml","form_type":"4"}},{"id":731922,"issuer":{"id":4972,"kind":"organization","name":"ARDELYX, INC."},"owners":[{"id":36785,"kind":"person","name":"Bertrand William C JR","position":1,"cik":"0001291937","reported_name":"Bertrand William C JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-18T20:02:46.000Z","date":"2026-06-16","kind":"grant","planned":false,"acquired":true,"shares":12345,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were issued pursuant to the Issuer's Non-Employee Director Compensation Program. The Reporting Person elected to receive stock in lieu of cash as permitted under the program."}],"balance_after":303052,"source":{"system":"sec-edgar","filing":"0001291937-26-000003","document":"wk-form4_1781812963.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1437402/000129193726000003/wk-form4_1781812963.xml","form_type":"4"}},{"id":1052726,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":36785,"kind":"person","name":"Bertrand William C JR","position":1,"cik":"0001291937","reported_name":"Bertrand William C JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares with a nominal value of GBP0.001 per share","published_at":"2025-08-29T22:25:42.000Z","date":"2025-08-28","kind":"sale","planned":false,"acquired":false,"shares":207000,"price":0.0101,"value":2090.7,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The ordinary shares whose sale is reported on this line are represented by American Depositary Shares (\"ADS\") and are held in the form of ADSs by the Reporting Person. Each ADS represents six ordinary shares of the Issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"The 207,000 ordinary shares reported in Column 4 are represented by 34,500 ADSs."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 of $0.01005 per ordinary share is derived from the sale price of $0.0603 per ADS divided by six. These ADSs were sold in multiple transactions at a price of $0.0603. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"The 986,352 ordinary shares reported in Column 5 are held in the form of 164,392 ADSs by the Reporting Person and represent solely those ADSs held by the Reporting Person following this transaction. Additionally, the Reporting Person holds RSU-style options and other options covering an aggregate of 16,108,722 ordinary shares of the Issuer."}],"balance_after":986352,"source":{"system":"sec-edgar","filing":"0001104659-25-085820","document":"tm2524763-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1291937/000110465925085820/tm2524763-1_4seq1.xml","form_type":"4"}},{"id":1103629,"issuer":{"id":4972,"kind":"organization","name":"ARDELYX, INC."},"owners":[{"id":36785,"kind":"person","name":"Bertrand William C JR","position":1,"cik":"0001291937","reported_name":"Bertrand William C JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-24T00:38:16.000Z","date":"2025-06-18","kind":"grant","planned":false,"acquired":true,"shares":54059,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date."}],"balance_after":54059,"derivative":{"exercise_price":3.61,"expiration_date":"2035-06-18","underlying":"Common Stock","underlying_shares":54059},"source":{"system":"sec-edgar","filing":"0001628280-25-032724","document":"wk-form4_1750725489.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1437402/000162828025032724/wk-form4_1750725489.xml","form_type":"4"}},{"id":1103628,"issuer":{"id":4972,"kind":"organization","name":"ARDELYX, INC."},"owners":[{"id":36785,"kind":"person","name":"Bertrand William C JR","position":1,"cik":"0001291937","reported_name":"Bertrand William C JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-24T00:38:16.000Z","date":"2025-06-18","kind":"grant","planned":false,"acquired":true,"shares":41551,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Restricted stock units (\"RSUs\"). The Reporting Person is entitled to receive one (1) shares of Common Stock for each one (1) RSU upon the vesting thereof.  The RSUs were issued pursuant to the Issuer's Non-Employee Director Compensation Program."}],"balance_after":290707,"source":{"system":"sec-edgar","filing":"0001628280-25-032724","document":"wk-form4_1750725489.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1437402/000162828025032724/wk-form4_1750725489.xml","form_type":"4"}},{"id":1103627,"issuer":{"id":4972,"kind":"organization","name":"ARDELYX, INC."},"owners":[{"id":36785,"kind":"person","name":"Bertrand William C JR","position":1,"cik":"0001291937","reported_name":"Bertrand William C JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-24T00:38:16.000Z","date":"2025-06-18","kind":"grant","planned":false,"acquired":true,"shares":19390,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were issued pursuant to the Issuer's Non-Employee Director Compensation Program. The Reporting Person elected to receive stock in lieu of cash as permitted under the program."}],"balance_after":249156,"source":{"system":"sec-edgar","filing":"0001628280-25-032724","document":"wk-form4_1750725489.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1437402/000162828025032724/wk-form4_1750725489.xml","form_type":"4"}},{"id":1255409,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":36785,"kind":"person","name":"Bertrand William C JR","position":1,"cik":"0001291937","reported_name":"Bertrand William C JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2025-02-20T22:35:34.000Z","date":"2025-02-20","kind":"grant","planned":false,"acquired":true,"shares":1074696,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$ 1.257137to GBP1.00.  The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Exercisable as to 268,674 Ordinary Shares on February 20, 2026 and will be exercisable as to the remainder in annual installments of 268,674 Ordinary Shares on the twentieth of each February from February 20, 2027 through February 20, 2029."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable."}],"balance_after":1074696,"derivative":{"exercise_price":0.0013,"underlying":"Ordinary Shares","underlying_shares":1074696},"source":{"system":"sec-edgar","filing":"0001104659-25-015746","document":"tm257186-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1291937/000110465925015746/tm257186-6_4seq1.xml","form_type":"4"}},{"id":1255408,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":36785,"kind":"person","name":"Bertrand William C JR","position":1,"cik":"0001291937","reported_name":"Bertrand William C JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2025-02-20T22:35:34.000Z","date":"2025-02-20","kind":"grant","planned":false,"acquired":true,"shares":1612032,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP0.08 based on an exchange rate of U.S.$ 1.257137 to GBP1.00. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable as to 403,008 Ordinary Shares on February 20, 2026 and will be exercisable as to the remainder in monthly installments of 33,582 Ordinary Shares on the twentieth of each month from March 20, 2026 through January 20, 2028 and 33,654 Ordinary Shares on February 20, 2029."}],"balance_after":1612032,"derivative":{"exercise_price":0.1,"expiration_date":"2035-02-20","underlying":"Ordinary Shares","underlying_shares":1612032},"source":{"system":"sec-edgar","filing":"0001104659-25-015746","document":"tm257186-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1291937/000110465925015746/tm257186-6_4seq1.xml","form_type":"4"}},{"id":1299906,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":36785,"kind":"person","name":"Bertrand William C JR","position":1,"cik":"0001291937","reported_name":"Bertrand William C JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2025-01-18T02:16:23.000Z","date":"2025-01-17","kind":"sale","planned":false,"acquired":false,"shares":5584,"price":0.5808,"value":3243.1872,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 17, 2023 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. Each exercise of the portion of these RSU-style share options and each sale reported in this Form 4 was effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.5797 to $0.589, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from each Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 191,382 ADSs and RSU-style options and other options covering an aggregate of 13,421,994 ordinary shares of the Issuer."}],"balance_after":7510,"source":{"system":"sec-edgar","filing":"0001104659-25-004606","document":"tm253716-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1291937/000110465925004606/tm253716-2_4seq1.xml","form_type":"4"}},{"id":1302439,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":36785,"kind":"person","name":"Bertrand William C JR","position":1,"cik":"0001291937","reported_name":"Bertrand William C JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2025-01-15T21:15:09.000Z","date":"2025-01-15","kind":"sale","planned":false,"acquired":false,"shares":9803,"price":0.5748,"value":5634.7644,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F7","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 15, 2024 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. Each exercise of the portion of these RSU-style share options and each sale reported in this Form 4 was effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.57 to $0.595, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F9","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from each Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 164,158 ADSs and RSU-style options and other options covering an aggregate of 13,500,558 ordinary shares of the Issuer."}],"balance_after":13756,"source":{"system":"sec-edgar","filing":"0001104659-25-003765","document":"tm253441-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1291937/000110465925003765/tm253441-1_4seq1.xml","form_type":"4"}},{"id":1302438,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":36785,"kind":"person","name":"Bertrand William C JR","position":1,"cik":"0001291937","reported_name":"Bertrand William C JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2025-01-15T21:15:09.000Z","date":"2025-01-13","kind":"sale","planned":false,"acquired":false,"shares":5471,"price":0.5879,"value":3216.4009,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F4","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 12, 2022 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. Each exercise of the portion of these RSU-style share options and each sale reported in this Form 4 was effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.58 to $0.603, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from each Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 164,158 ADSs and RSU-style options and other options covering an aggregate of 13,500,558 ordinary shares of the Issuer."}],"balance_after":7623,"source":{"system":"sec-edgar","filing":"0001104659-25-003765","document":"tm253441-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1291937/000110465925003765/tm253441-1_4seq1.xml","form_type":"4"}},{"id":1302437,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":36785,"kind":"person","name":"Bertrand William C JR","position":1,"cik":"0001291937","reported_name":"Bertrand William C JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2025-01-15T21:15:09.000Z","date":"2025-01-13","kind":"sale","planned":false,"acquired":false,"shares":4268,"price":0.5879,"value":2509.1572,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 11, 2021 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. Each exercise of the portion of these RSU-style share options and each sale reported in this Form 4 was effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.58 to $0.603, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from each Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 164,158 ADSs and RSU-style options and other options covering an aggregate of 13,500,558 ordinary shares of the Issuer."}],"balance_after":5845,"source":{"system":"sec-edgar","filing":"0001104659-25-003765","document":"tm253441-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1291937/000110465925003765/tm253441-1_4seq1.xml","form_type":"4"}},{"id":1477193,"issuer":{"id":4972,"kind":"organization","name":"ARDELYX, INC."},"owners":[{"id":36785,"kind":"person","name":"Bertrand William C JR","position":1,"cik":"0001291937","reported_name":"Bertrand William C JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-17T22:52:13.000Z","date":"2024-06-14","kind":"grant","planned":false,"acquired":true,"shares":40243,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date."}],"balance_after":40243,"derivative":{"exercise_price":6.35,"expiration_date":"2034-06-14","underlying":"Common Stock","underlying_shares":40243},"source":{"system":"sec-edgar","filing":"0001628280-24-028600","document":"wk-form4_1718664726.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1437402/000162828024028600/wk-form4_1718664726.xml","form_type":"4"}},{"id":1477192,"issuer":{"id":4972,"kind":"organization","name":"ARDELYX, INC."},"owners":[{"id":36785,"kind":"person","name":"Bertrand William C JR","position":1,"cik":"0001291937","reported_name":"Bertrand William C JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-17T22:52:13.000Z","date":"2024-06-14","kind":"grant","planned":false,"acquired":true,"shares":11023,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were issued pursuant to the Issuer's Non-Employee Director Compensation Program. The Reporting Person elected to receive stock in lieu of cash as permitted under the program."}],"balance_after":229766,"source":{"system":"sec-edgar","filing":"0001628280-24-028600","document":"wk-form4_1718664726.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1437402/000162828024028600/wk-form4_1718664726.xml","form_type":"4"}},{"id":1677683,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":36785,"kind":"person","name":"Bertrand William C JR","position":1,"cik":"0001291937","reported_name":"Bertrand William C JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2024-01-17T22:30:20.000Z","date":"2024-01-17","kind":"sale","planned":false,"acquired":false,"shares":13599,"price":0.673,"value":9152.127,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F7","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of 100% of an RSU-style share option covering ordinary shares of the Issuer granted on January 17, 2023 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.67 to $0.73, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F9","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 129,149 ADSs and RSU-style options and other options covering an aggregate of 13,781,154 ordinary shares of the Issuer."}],"balance_after":20201,"source":{"system":"sec-edgar","filing":"0001104659-24-004560","document":"tm243270-13_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1291937/000110465924004560/tm243270-13_4seq1.xml","form_type":"4"}},{"id":1677682,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":36785,"kind":"person","name":"Bertrand William C JR","position":1,"cik":"0001291937","reported_name":"Bertrand William C JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2024-01-17T22:30:20.000Z","date":"2024-01-17","kind":"sale","planned":false,"acquired":false,"shares":5309,"price":0.673,"value":3572.957,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F4","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 17, 2023 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.67 to $0.73, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 129,149 ADSs and RSU-style options and other options covering an aggregate of 13,781,154 ordinary shares of the Issuer."}],"balance_after":7785,"source":{"system":"sec-edgar","filing":"0001104659-24-004560","document":"tm243270-13_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1291937/000110465924004560/tm243270-13_4seq1.xml","form_type":"4"}},{"id":1677681,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":36785,"kind":"person","name":"Bertrand William C JR","position":1,"cik":"0001291937","reported_name":"Bertrand William C JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2024-01-17T22:30:20.000Z","date":"2024-01-16","kind":"sale","planned":false,"acquired":false,"shares":4681,"price":0.79,"value":3697.99,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 16, 2020 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is the sale price per ADS."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 129,149 ADSs and RSU-style options and other options covering an aggregate of 13,781,154 ordinary shares of the Issuer."}],"balance_after":7023,"source":{"system":"sec-edgar","filing":"0001104659-24-004560","document":"tm243270-13_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1291937/000110465924004560/tm243270-13_4seq1.xml","form_type":"4"}},{"id":1677680,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":36785,"kind":"person","name":"Bertrand William C JR","position":1,"cik":"0001291937","reported_name":"Bertrand William C JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2024-01-17T22:03:43.000Z","date":"2024-01-15","kind":"grant","planned":false,"acquired":true,"shares":565416,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$ 1.274570 to GBP1.00. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Exercisable as to 141,354 Ordinary Shares on January 15, 2025 and will be exercisable as to the remainder in annual installments of 141,354 Ordinary Shares on the fifteenth of each January from January 15, 2026 through January 15, 2028."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable."}],"balance_after":565416,"derivative":{"exercise_price":0.0013,"underlying":"Ordinary Shares","underlying_shares":565416},"source":{"system":"sec-edgar","filing":"0001104659-24-004531","document":"tm243270-12_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1291937/000110465924004531/tm243270-12_4seq1.xml","form_type":"4"}},{"id":1677679,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":36785,"kind":"person","name":"Bertrand William C JR","position":1,"cik":"0001291937","reported_name":"Bertrand William C JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2024-01-17T22:03:43.000Z","date":"2024-01-15","kind":"grant","planned":false,"acquired":true,"shares":2544432,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP0.11 based on an exchange rate of U.S.$ 1.274570 to GBP1.00. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable as to 636,108 Ordinary Shares on January 15, 2025 and will be exercisable as to the remainder in monthly installments of 53,004 Ordinary Shares on the fifteenth of each month from February 15, 2025 through December 15, 2027 and 53,184 Ordinary Shares on January 15, 2028."}],"balance_after":2544432,"derivative":{"exercise_price":0.14,"expiration_date":"2034-01-15","underlying":"Ordinary Shares","underlying_shares":2544432},"source":{"system":"sec-edgar","filing":"0001104659-24-004531","document":"tm243270-12_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1291937/000110465924004531/tm243270-12_4seq1.xml","form_type":"4"}},{"id":1679902,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":36785,"kind":"person","name":"Bertrand William C JR","position":1,"cik":"0001291937","reported_name":"Bertrand William C JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2024-01-12T22:00:44.000Z","date":"2024-01-12","kind":"sale","planned":false,"acquired":false,"shares":5220,"price":0.8541,"value":4458.402,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F4","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 12, 2022 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. Each exercise of the portion of these RSU-style share options and each sale reported in this Form 4 was effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.813 to $0.88, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from each Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 115,171 ADSs and RSU-style options and other options covering an aggregate of 11,022,894 ordinary shares of the Issuer."}],"balance_after":7874,"source":{"system":"sec-edgar","filing":"0001104659-24-003745","document":"tm243270-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1291937/000110465924003745/tm243270-4_4seq1.xml","form_type":"4"}},{"id":1679901,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":36785,"kind":"person","name":"Bertrand William C JR","position":1,"cik":"0001291937","reported_name":"Bertrand William C JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2024-01-12T22:00:44.000Z","date":"2024-01-11","kind":"sale","planned":false,"acquired":false,"shares":4009,"price":0.8367,"value":3354.3303,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 11, 2021 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. Each exercise of the portion of these RSU-style share options and each sale reported in this Form 4 was effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.80 to $0.88, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from each Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 115,171 ADSs and RSU-style options and other options covering an aggregate of 11,022,894 ordinary shares of the Issuer."}],"balance_after":6104,"source":{"system":"sec-edgar","filing":"0001104659-24-003745","document":"tm243270-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1291937/000110465924003745/tm243270-4_4seq1.xml","form_type":"4"}},{"id":1851965,"issuer":{"id":4972,"kind":"organization","name":"ARDELYX, INC."},"owners":[{"id":36785,"kind":"person","name":"Bertrand William C JR","position":1,"cik":"0001291937","reported_name":"Bertrand William C JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-16T22:29:45.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":49237,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date."}],"balance_after":49237,"derivative":{"exercise_price":3.92,"expiration_date":"2033-06-15","underlying":"Common Stock","underlying_shares":49237},"source":{"system":"sec-edgar","filing":"0001628280-23-022555","document":"wk-form4_1686954576.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1437402/000162828023022555/wk-form4_1686954576.xml","form_type":"4"}},{"id":1851964,"issuer":{"id":4972,"kind":"organization","name":"ARDELYX, INC."},"owners":[{"id":36785,"kind":"person","name":"Bertrand William C JR","position":1,"cik":"0001291937","reported_name":"Bertrand William C JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-16T22:29:45.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":16581,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were issued pursuant to the Issuer's Non-Employee Director Compensation Program. The Reporting Person elected to receive stock in lieu of cash as permitted under the program."}],"balance_after":218743,"source":{"system":"sec-edgar","filing":"0001628280-23-022555","document":"wk-form4_1686954576.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1437402/000162828023022555/wk-form4_1686954576.xml","form_type":"4"}},{"id":2053646,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":36785,"kind":"person","name":"Bertrand William C JR","position":1,"cik":"0001291937","reported_name":"Bertrand William C JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2023-01-18T02:17:05.000Z","date":"2023-01-17","kind":"sale","acquired":false,"shares":4440,"price":1.858,"value":8249.52,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 16, 2020 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $1.82 to $1.87, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 107,907 ADSs and RSU-style options and other options covering an aggregate of 11,162,136 ordinary shares of the Issuer."}],"balance_after":7264,"source":{"system":"sec-edgar","filing":"0001104659-23-004381","document":"tm231655-19_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1291937/000110465923004381/tm231655-19_4seq1.xml","form_type":"4"}},{"id":2053645,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":36785,"kind":"person","name":"Bertrand William C JR","position":1,"cik":"0001291937","reported_name":"Bertrand William C JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2023-01-18T02:07:15.000Z","date":"2023-01-17","kind":"grant","acquired":true,"shares":202800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.219333 to GBP1.00. The actual exercise price will be the pounds sterling amount."}],"balance_after":202800,"derivative":{"exercise_price":0.0012,"exercise_date":"2024-01-17","expiration_date":"2025-03-15","underlying":"Ordinary Shares","underlying_shares":202800},"source":{"system":"sec-edgar","filing":"0001104659-23-004377","document":"tm231655-16_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1291937/000110465923004377/tm231655-16_4seq1.xml","form_type":"4"}},{"id":2053644,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":36785,"kind":"person","name":"Bertrand William C JR","position":1,"cik":"0001291937","reported_name":"Bertrand William C JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2023-01-18T02:07:15.000Z","date":"2023-01-17","kind":"grant","acquired":true,"shares":314256,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$ 1.219333 to GBP1.00. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Exercisable as to 78,564 Ordinary Shares on January 17, 2024 and will be exercisable as to the remainder in annual installments of 78,564 Ordinary Shares on the seventeenth of each January from January 17, 2025 through January 17, 2027."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable."}],"balance_after":314256,"derivative":{"exercise_price":0.0012,"underlying":"Ordinary Shares","underlying_shares":314256},"source":{"system":"sec-edgar","filing":"0001104659-23-004377","document":"tm231655-16_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1291937/000110465923004377/tm231655-16_4seq1.xml","form_type":"4"}},{"id":2053643,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":36785,"kind":"person","name":"Bertrand William C JR","position":1,"cik":"0001291937","reported_name":"Bertrand William C JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2023-01-18T02:07:15.000Z","date":"2023-01-17","kind":"grant","acquired":true,"shares":1407072,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP0.26 based on an exchange rate of U.S.$ 1.219333 to GBP1.00. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable as to 351,768 Ordinary Shares on January 17, 2024 and will be exercisable as to the remainder in monthly installments of 29,310 Ordinary Shares on the seventeenth of each month from February 17, 2024 through December 17, 2026 and 29,454 Ordinary Shares on January 17, 2027."}],"balance_after":1407072,"derivative":{"exercise_price":0.31,"expiration_date":"2033-01-17","underlying":"Ordinary Shares","underlying_shares":1407072},"source":{"system":"sec-edgar","filing":"0001104659-23-004377","document":"tm231655-16_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1291937/000110465923004377/tm231655-16_4seq1.xml","form_type":"4"}},{"id":2055530,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":36785,"kind":"person","name":"Bertrand William C JR","position":1,"cik":"0001291937","reported_name":"Bertrand William C JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2023-01-13T02:03:45.000Z","date":"2023-01-12","kind":"sale","acquired":false,"shares":4973,"price":1.706,"value":8483.938,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F4","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 12, 2022 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. Each exercise of the portion of these RSU-style share options and each sale reported in this Form 4 was effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $1.70 to $1.79, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from each Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 93,516 ADSs and RSU-style options and other options covering an aggregate of 9,308,232 ordinary shares of the Issuer."}],"balance_after":8121,"source":{"system":"sec-edgar","filing":"0001104659-23-003539","document":"tm231655-8_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1291937/000110465923003539/tm231655-8_4seq1.xml","form_type":"4"}},{"id":2055529,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":36785,"kind":"person","name":"Bertrand William C JR","position":1,"cik":"0001291937","reported_name":"Bertrand William C JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2023-01-13T02:03:45.000Z","date":"2023-01-11","kind":"sale","acquired":false,"shares":3843,"price":1.7468,"value":6712.9524,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 11, 2021 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. Each exercise of the portion of these RSU-style share options and each sale reported in this Form 4 was effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $1.73 to $1.76, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from each Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 93,516 ADSs and RSU-style options and other options covering an aggregate of 9,308,232 ordinary shares of the Issuer."}],"balance_after":6270,"source":{"system":"sec-edgar","filing":"0001104659-23-003539","document":"tm231655-8_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1291937/000110465923003539/tm231655-8_4seq1.xml","form_type":"4"}},{"id":2066637,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":36785,"kind":"person","name":"Bertrand William C JR","position":1,"cik":"0001291937","reported_name":"Bertrand William C JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2023-01-05T02:02:41.000Z","date":"2023-01-04","kind":"sale","acquired":false,"shares":3584,"price":1.694,"value":6071.296,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 4, 2019 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price based on prices ranging from $1.65 to $1.73, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 87,735 ADSs and RSU-style options and other options covering an aggregate of 9,447,474 ordinary shares of the Issuer."}],"balance_after":5781,"source":{"system":"sec-edgar","filing":"0001104659-23-001092","document":"tm231655-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1291937/000110465923001092/tm231655-4_4seq1.xml","form_type":"4"}},{"id":2227515,"issuer":{"id":4972,"kind":"organization","name":"ARDELYX, INC."},"owners":[{"id":36785,"kind":"person","name":"Bertrand William C JR","position":1,"cik":"0001291937","reported_name":"Bertrand William C JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-17T20:23:54.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date."}],"balance_after":100000,"derivative":{"exercise_price":0.548,"expiration_date":"2032-06-15","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001567619-22-013089","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1437402/000156761922013089/doc1.xml","form_type":"4"}},{"id":2227514,"issuer":{"id":4972,"kind":"organization","name":"ARDELYX, INC."},"owners":[{"id":36785,"kind":"person","name":"Bertrand William C JR","position":1,"cik":"0001291937","reported_name":"Bertrand William C JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-17T20:23:54.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":118613,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were issued pursuant to the Issuer's Non-Employee Director Compensation Program. The Reporting Person elected to receive stock in lieu of cash as permitted under the program."}],"balance_after":202162,"source":{"system":"sec-edgar","filing":"0001567619-22-013089","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1437402/000156761922013089/doc1.xml","form_type":"4"}},{"id":2433586,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":36785,"kind":"person","name":"Bertrand William C JR","position":1,"cik":"0001291937","reported_name":"Bertrand William C JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2022-01-19T02:04:19.000Z","date":"2022-01-18","kind":"sale","acquired":false,"shares":4368,"price":3.1918,"value":13941.7824,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 16, 2020 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $3.17 to $3.22, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 80,399 ADSs and RSU-style options and other options covering an aggregate of 9,503,664 ordinary shares of the Issuer."}],"balance_after":7336,"source":{"system":"sec-edgar","filing":"0001104659-22-005056","document":"tm221700-18_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1291937/000110465922005056/tm221700-18_4seq1.xml","form_type":"4"}},{"id":2435827,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":36785,"kind":"person","name":"Bertrand William C JR","position":1,"cik":"0001291937","reported_name":"Bertrand William C JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2022-01-14T02:02:48.000Z","date":"2022-01-12","kind":"sale","acquired":false,"shares":2248,"price":3.5441,"value":7967.1368,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F4","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 12, 2018 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. Each exercise of the portion of these RSU-style share options and each sale reported in this Form 4 was effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $3.53 to $3.55, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from each Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 70,302 ADSs and RSU-style options and other options covering an aggregate of 9,573,888 ordinary shares of the Issuer."}],"balance_after":3754,"source":{"system":"sec-edgar","filing":"0001104659-22-004153","document":"tm221700-14_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1291937/000110465922004153/tm221700-14_4seq1.xml","form_type":"4"}},{"id":2435826,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":36785,"kind":"person","name":"Bertrand William C JR","position":1,"cik":"0001291937","reported_name":"Bertrand William C JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2022-01-14T02:02:48.000Z","date":"2022-01-11","kind":"sale","acquired":false,"shares":3770,"price":3.5567,"value":13408.759,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 11, 2021 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. Each exercise of the portion of these RSU-style share options and each sale reported in this Form 4 was effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $3.48 to $3.64, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from each Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 70,302 ADSs and RSU-style options and other options covering an aggregate of 9,573,888 ordinary shares of the Issuer."}],"balance_after":6343,"source":{"system":"sec-edgar","filing":"0001104659-22-004153","document":"tm221700-14_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1291937/000110465922004153/tm221700-14_4seq1.xml","form_type":"4"}},{"id":2435825,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":36785,"kind":"person","name":"Bertrand William C JR","position":1,"cik":"0001291937","reported_name":"Bertrand William C JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2022-01-14T02:00:31.000Z","date":"2022-01-12","kind":"grant","acquired":true,"shares":314256,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$ 1.362272 to GBP1.00. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Exercisable as to 78,564 Ordinary Shares on January 12, 2023 and will be exercisable as to the remainder in annual installments of 78,564 Ordinary Shares on the twelfth of each January from January 12, 2024 through January 12, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable."}],"balance_after":314256,"derivative":{"exercise_price":0.0014,"underlying":"Ordinary Shares","underlying_shares":314256},"source":{"system":"sec-edgar","filing":"0001104659-22-004148","document":"tm221700-10_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1291937/000110465922004148/tm221700-10_4seq1.xml","form_type":"4"}},{"id":2435824,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":36785,"kind":"person","name":"Bertrand William C JR","position":1,"cik":"0001291937","reported_name":"Bertrand William C JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2022-01-14T02:00:31.000Z","date":"2022-01-12","kind":"grant","acquired":true,"shares":1407072,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP0.44 based on an exchange rate of U.S.$ 1.362272 to GBP1.00. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable as to 351,768 Ordinary Shares on January 12, 2023 and will be exercisable as to the remainder in monthly installments of 29,310 Ordinary Shares on the twelfth of each month from February 12, 2023 through December 12, 2025 and 29,454 Ordinary Shares on January 12, 2026."}],"balance_after":1407072,"derivative":{"exercise_price":0.6,"expiration_date":"2032-01-12","underlying":"Ordinary Shares","underlying_shares":1407072},"source":{"system":"sec-edgar","filing":"0001104659-22-004148","document":"tm221700-10_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1291937/000110465922004148/tm221700-10_4seq1.xml","form_type":"4"}},{"id":2443420,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":36785,"kind":"person","name":"Bertrand William C JR","position":1,"cik":"0001291937","reported_name":"Bertrand William C JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2022-01-06T02:08:26.000Z","date":"2022-01-04","kind":"sale","acquired":false,"shares":3490,"price":4.0642,"value":14184.058,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 4, 2019 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price based on prices ranging from $4.04 to $4.10, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 64,429 ADSs and RSU-style options and other options covering an aggregate of 7,949,250 ordinary shares of the Issuer."}],"balance_after":5873,"source":{"system":"sec-edgar","filing":"0001104659-22-001671","document":"tm221700-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1291937/000110465922001671/tm221700-4_4seq1.xml","form_type":"4"}},{"id":2644159,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":36785,"kind":"person","name":"Bertrand William C JR","position":1,"cik":"0001291937","reported_name":"Bertrand William C JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2021-07-03T00:01:31.000Z","date":"2021-07-02","kind":"sale","acquired":false,"shares":4375,"price":4.2649,"value":18658.9375,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 16, 2020 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $4.26 to $4.30, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 57,100 ADSs and RSU-style options and other options covering an aggregate of 8,005,428 ordinary shares of the Issuer."}],"balance_after":7329,"source":{"system":"sec-edgar","filing":"0001104659-21-089050","document":"tm2121284-9_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1291937/000110465921089050/tm2121284-9_4seq1.xml","form_type":"4"}},{"id":2660789,"issuer":{"id":4972,"kind":"organization","name":"ARDELYX, INC."},"owners":[{"id":36785,"kind":"person","name":"Bertrand William C JR","position":1,"cik":"0001291937","reported_name":"Bertrand William C JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-21T20:11:44.000Z","date":"2021-06-16","kind":"grant","acquired":true,"shares":32765,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date."}],"balance_after":32765,"derivative":{"exercise_price":7.31,"expiration_date":"2031-06-16","underlying":"Common Stock","underlying_shares":32765},"source":{"system":"sec-edgar","filing":"0001567619-21-012431","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1437402/000156761921012431/doc1.xml","form_type":"4"}},{"id":2660788,"issuer":{"id":4972,"kind":"organization","name":"ARDELYX, INC."},"owners":[{"id":36785,"kind":"person","name":"Bertrand William C JR","position":1,"cik":"0001291937","reported_name":"Bertrand William C JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-21T20:11:44.000Z","date":"2021-06-16","kind":"grant","acquired":true,"shares":8891,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were issued pursuant to the Issuer's Non-Employee Director Compensation Program. The Reporting Person elected to receive stock in lieu of cash as permitted under the program."}],"balance_after":83549,"source":{"system":"sec-edgar","filing":"0001567619-21-012431","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1437402/000156761921012431/doc1.xml","form_type":"4"}},{"id":2909451,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":36785,"kind":"person","name":"Bertrand William C JR","position":1,"cik":"0001291937","reported_name":"Bertrand William C JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2021-01-13T02:01:44.000Z","date":"2021-01-12","kind":"sale","acquired":false,"shares":2234,"price":6.1522,"value":13744.0148,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 12, 2018 and which vested on January 12, 2021. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $6.15 to $6.22, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 53,332 ADSs and RSU-style options and other options covering an aggregate of 8,075,652 ordinary shares of the Issuer."}],"balance_after":3768,"source":{"system":"sec-edgar","filing":"0001104659-21-003594","document":"tm212950-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1291937/000110465921003594/tm212950-4_4seq1.xml","form_type":"4"}},{"id":2910796,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":36785,"kind":"person","name":"Bertrand William C JR","position":1,"cik":"0001291937","reported_name":"Bertrand William C JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2021-01-12T02:00:27.000Z","date":"2021-01-11","kind":"grant","acquired":true,"shares":242712,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$ 1.358422 to GBP1.00. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Exercisable as to 60,678 Ordinary Shares on January 11, 2022 and will be exercisable as to the remainder in annual installments of 60,678 Ordinary Shares on the eleventh of each January from January 11, 2023 through January 11, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable."}],"balance_after":242712,"derivative":{"exercise_price":0.0014,"underlying":"Ordinary Shares","underlying_shares":242712},"source":{"system":"sec-edgar","filing":"0001104659-21-003129","document":"tm212800-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1291937/000110465921003129/tm212800-1_4seq1.xml","form_type":"4"}},{"id":2910795,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":36785,"kind":"person","name":"Bertrand William C JR","position":1,"cik":"0001291937","reported_name":"Bertrand William C JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2021-01-12T02:00:27.000Z","date":"2021-01-11","kind":"grant","acquired":true,"shares":1086816,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP0.76 based on an exchange rate of U.S.$ 1.358422 to GBP1.00. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable as to 271,704 Ordinary Shares on January 11, 2022 and will be exercisable as to the remainder in monthly installments of 22,638 Ordinary Shares on the eleventh of each month from February 11, 2022 through December 11, 2024 and 22,782 Ordinary Shares on January 11, 2025."}],"balance_after":1086816,"derivative":{"exercise_price":1.03,"expiration_date":"2031-01-11","underlying":"Ordinary Shares","underlying_shares":1086816},"source":{"system":"sec-edgar","filing":"0001104659-21-003129","document":"tm212800-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1291937/000110465921003129/tm212800-1_4seq1.xml","form_type":"4"}},{"id":4612736,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":36785,"kind":"person","name":"Bertrand William C JR","position":1,"cik":"0001291937","reported_name":"Bertrand William C JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2021-01-06T02:01:29.000Z","date":"2021-01-04","kind":"sale","acquired":false,"shares":3499,"price":5.3279,"value":18642.3221,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 4, 2019 and which vested on January 4, 2021. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $5.265 to $5.45, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 47,468 ADSs and RSU-style options and other options covering an aggregate of 6,782,136 ordinary shares of the Issuer."}],"balance_after":5864,"source":{"system":"sec-edgar","filing":"0001104659-21-001177","document":"tm211506-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1291937/000110465921001177/tm211506-3_4seq1.xml","form_type":"4"}},{"id":2944221,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":36785,"kind":"person","name":"Bertrand William C JR","position":1,"cik":"0001291937","reported_name":"Bertrand William C JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares with a nominal value of GBP0.001 per share","published_at":"2020-12-16T02:00:38.000Z","date":"2020-12-14","kind":"purchase","acquired":true,"shares":207000,"price":0.6948,"value":143823.6,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares (\"ADS\") and are held in the form of ADSs by William Bertrand. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc."},{"field":"shares","element":"transactionShares","label":"F2","text":"The 207,000 ordinary shares reported in Column 4 are represented by 34,500 ADSs."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 of $0.6948 per ordinary share is derived from the purchase price paid on December 14, 2020 of $4.1688 per ADS divided by six. The purchase price per ADS is a weighted average price. These ADSs were purchased in multiple transactions at prices ranging from $4.14 to $4.17, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs purchased at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"The 284,808 ordinary shares reported in Column 5 include 77,808 ordinary shares represented by 12,968 ADSs owned by Mr. Bertrand prior to the purchase reported in Column 4. These shares are held in the form of ADSs by Mr. Bertrand."}],"balance_after":284808,"source":{"system":"sec-edgar","filing":"0001104659-20-135891","document":"tm2038497-1_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1291937/000110465920135891/tm2038497-1_4.xml","form_type":"4"}},{"id":2944311,"issuer":{"id":4972,"kind":"organization","name":"ARDELYX, INC."},"owners":[{"id":36785,"kind":"person","name":"Bertrand William C JR","position":1,"cik":"0001291937","reported_name":"Bertrand William C JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-12-15T21:22:53.000Z","date":"2020-12-14","kind":"grant","acquired":true,"shares":15000,"price":7.0837,"value":106255.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This transaction was executed in multiple trades in prices ranging from $7.08 to $7.10, inclusive. The price reported in Column 4 above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades in prices ranging from $7.08 to $7.10, inclusive. The price reported in Column 4 above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote."}],"balance_after":74658,"source":{"system":"sec-edgar","filing":"0001567619-20-021092","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1437402/000156761920021092/doc1.xml","form_type":"4"}},{"id":3113288,"issuer":{"id":4972,"kind":"organization","name":"ARDELYX, INC."},"owners":[{"id":36785,"kind":"person","name":"Bertrand William C JR","position":1,"cik":"0001291937","reported_name":"Bertrand William C JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-11T22:34:07.000Z","date":"2020-06-09","kind":"grant","acquired":true,"shares":23500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date."}],"balance_after":23500,"derivative":{"exercise_price":7.31,"expiration_date":"2030-06-09","underlying":"Common Stock","underlying_shares":23500},"source":{"system":"sec-edgar","filing":"0001567619-20-012034","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1437402/000156761920012034/doc1.xml","form_type":"4"}},{"id":3113287,"issuer":{"id":4972,"kind":"organization","name":"ARDELYX, INC."},"owners":[{"id":36785,"kind":"person","name":"Bertrand William C JR","position":1,"cik":"0001291937","reported_name":"Bertrand William C JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-11T22:34:07.000Z","date":"2020-06-09","kind":"grant","acquired":true,"shares":7523,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were issued pursuant to the Issuer's Non-Employee Director Compensation Program.  The Reporting Person elected to receive stock in lieu of cash as permitted under the program."}],"balance_after":59658,"source":{"system":"sec-edgar","filing":"0001567619-20-012034","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1437402/000156761920012034/doc1.xml","form_type":"4"}},{"id":3307649,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":36785,"kind":"person","name":"Bertrand William C JR","position":1,"cik":"0001291937","reported_name":"Bertrand William C JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2020-01-18T02:31:58.000Z","date":"2020-01-16","kind":"grant","acquired":true,"shares":280896,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S$1.302659 to GBP1.00.  The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Exercisable as to 70,224 Ordinary Shares on January 16, 2021 and will be exercisable as to the remainder in annual installments of 70,224 Ordinary Shares on January 16, 2022 and January 16, 2023 and 70,224 Ordinary Shares on January 16, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable."}],"balance_after":280896,"derivative":{"exercise_price":0.0013,"underlying":"Ordinary Shares","underlying_shares":280896},"source":{"system":"sec-edgar","filing":"0001104659-20-005258","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1291937/000110465920005258/a4.xml","form_type":"4"}},{"id":3307648,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":36785,"kind":"person","name":"Bertrand William C JR","position":1,"cik":"0001291937","reported_name":"Bertrand William C JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2020-01-18T02:31:58.000Z","date":"2020-01-16","kind":"grant","acquired":true,"shares":1257744,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP0.57 based on an exchange rate of U.S$1.302659 to GBP1.00.  The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable as to 314,436 Ordinary Shares on January 16, 2021 and will be exercisable as to the remainder in monthly installments of 26,202 Ordinary Shares on the sixteenth of each month from February 16, 2021 through December 16, 2023 and 26,238 Ordinary Shares on January 16, 2024."}],"balance_after":1257744,"derivative":{"exercise_price":0.74,"expiration_date":"2030-01-16","underlying":"Ordinary Shares","underlying_shares":1257744},"source":{"system":"sec-edgar","filing":"0001104659-20-005258","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1291937/000110465920005258/a4.xml","form_type":"4"}},{"id":3310673,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":36785,"kind":"person","name":"Bertrand William C JR","position":1,"cik":"0001291937","reported_name":"Bertrand William C JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2020-01-16T01:03:13.000Z","date":"2020-01-14","kind":"sale","acquired":false,"shares":2397,"price":5.1347,"value":12307.8759,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 12, 2018 and which vested on January 12, 2020. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $5.12 to $5.18, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the ADSs sold at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 9,363ADSs and RSU-style options and other options covering an aggregate of 5,299,674 ordinary shares of the Issuer."}],"balance_after":3605,"source":{"system":"sec-edgar","filing":"0001104659-20-004423","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1291937/000110465920004423/a4.xml","form_type":"4"}},{"id":3316154,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":36785,"kind":"person","name":"Bertrand William C JR","position":1,"cik":"0001291937","reported_name":"Bertrand William C JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2020-01-08T01:01:14.000Z","date":"2020-01-06","kind":"sale","acquired":false,"shares":3731,"price":1.2,"value":4477.2,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 4, 2019 and which vested on January 4, 2020. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $1.20 to $1.2008, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the ADSs sold at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 3,731 ADSs and RSU-style options and other options covering an aggregate of 5,335,686 ordinary shares of the Issuer"}],"balance_after":5632,"source":{"system":"sec-edgar","filing":"0001104659-20-002081","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1291937/000110465920002081/a4.xml","form_type":"4"}},{"id":3487624,"issuer":{"id":4972,"kind":"organization","name":"ARDELYX, INC."},"owners":[{"id":36785,"kind":"person","name":"Bertrand William C JR","position":1,"cik":"0001291937","reported_name":"Bertrand William C JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-06-17T20:31:47.000Z","date":"2019-06-13","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date."}],"balance_after":50000,"derivative":{"exercise_price":2.74,"expiration_date":"2029-06-13","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001567619-19-013481","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1437402/000156761919013481/doc1.xml","form_type":"4"}},{"id":3487623,"issuer":{"id":4972,"kind":"organization","name":"ARDELYX, INC."},"owners":[{"id":36785,"kind":"person","name":"Bertrand William C JR","position":1,"cik":"0001291937","reported_name":"Bertrand William C JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-17T20:31:47.000Z","date":"2019-06-13","kind":"grant","acquired":true,"shares":18248,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were issued pursuant to the Issuer's Non-Employee Director Compensation Program.  The Reporting Person elected to receive stock in lieu of cash as permitted under the program."}],"balance_after":52135,"source":{"system":"sec-edgar","filing":"0001567619-19-013481","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1437402/000156761919013481/doc1.xml","form_type":"4"}},{"id":3694458,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":36785,"kind":"person","name":"Bertrand William C JR","position":1,"cik":"0001291937","reported_name":"Bertrand William C JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2019-01-17T02:31:41.000Z","date":"2019-01-14","kind":"sale","acquired":false,"shares":2271,"price":5.3694,"value":12193.9074,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 12, 2018 and which vested on January 12, 2019. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $5.21 to $5.70, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the ADSs sold at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds RSU-style options and other options covering an aggregate of 5,391,864 ordinary shares of the Issuer."}],"balance_after":3731,"source":{"system":"sec-edgar","filing":"0001104659-19-002165","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1291937/000110465919002165/a4.xml","form_type":"4"}},{"id":3700021,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":36785,"kind":"person","name":"Bertrand William C JR","position":1,"cik":"0001291937","reported_name":"Bertrand William C JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2019-01-09T02:02:22.000Z","date":"2019-01-04","kind":"grant","acquired":true,"shares":224724,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.26332 - GBP1.00.  The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Exercisable as to 56,178 Ordinary Shares on January 4, 2020 and will be exercisable as to the remainder in annual installments of 56,178 Ordinary Shares on January 4, 2021 and January 4, 2022 and 56,190 Ordinary Shares on January 4, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable."}],"balance_after":224724,"derivative":{"exercise_price":0.0013,"underlying":"Ordinary Shares","underlying_shares":224724},"source":{"system":"sec-edgar","filing":"0001104659-19-001304","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1291937/000110465919001304/a4.xml","form_type":"4"}},{"id":3700020,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":36785,"kind":"person","name":"Bertrand William C JR","position":1,"cik":"0001291937","reported_name":"Bertrand William C JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2019-01-09T02:02:22.000Z","date":"2019-01-04","kind":"grant","acquired":true,"shares":1006224,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP0.70 based on an exchange rate of $U.S. 1.26332 - GBP1.00.  The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable as to 251,556 Ordinary Shares on January 4, 2020 and will be exercisable as to the remainder in monthly installments of 20,958 Ordinary Shares on the fourth of each month from February 4, 2020 through December 4, 2022 and 21,138 Ordinary Shares on January 4, 2023."}],"balance_after":1006224,"derivative":{"exercise_price":0.89,"expiration_date":"2029-01-04","underlying":"Ordinary Shares","underlying_shares":1006224},"source":{"system":"sec-edgar","filing":"0001104659-19-001304","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1291937/000110465919001304/a4.xml","form_type":"4"}},{"id":3892492,"issuer":{"id":4972,"kind":"organization","name":"ARDELYX, INC."},"owners":[{"id":36785,"kind":"person","name":"Bertrand William C JR","position":1,"cik":"0001291937","reported_name":"Bertrand William C JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-06-15T22:57:52.000Z","date":"2018-06-13","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date."}],"balance_after":15000,"derivative":{"exercise_price":4.03,"expiration_date":"2028-06-13","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001140361-18-028863","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1437402/000114036118028863/doc1.xml","form_type":"4"}},{"id":3892491,"issuer":{"id":4972,"kind":"organization","name":"ARDELYX, INC."},"owners":[{"id":36785,"kind":"person","name":"Bertrand William C JR","position":1,"cik":"0001291937","reported_name":"Bertrand William C JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-06-15T22:57:52.000Z","date":"2018-06-13","kind":"grant","acquired":true,"shares":12406,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were issued pursuant to the Issuer's Non-Employee Director Compensation Program. The Reporting Person elected to receive stock in lieu of cash as permitted under the program."}],"balance_after":33887,"source":{"system":"sec-edgar","filing":"0001140361-18-028863","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1437402/000114036118028863/doc1.xml","form_type":"4"}},{"id":4097704,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":36785,"kind":"person","name":"Bertrand William C JR","position":1,"cik":"0001291937","reported_name":"Bertrand William C JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2018-01-17T22:20:36.000Z","date":"2018-01-12","kind":"grant","acquired":true,"shares":144048,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.3542 - GBP1.00.  The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Exercisable as to 36,012 Ordinary Shares on January 12, 2019 and will be exercisable as to the remainder in annual installments of 36,012 Ordinary Shares on the twelfth of each January from January 12, 2020 through January 12, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable."}],"balance_after":144048,"derivative":{"exercise_price":0.0014,"underlying":"Ordinary Shares","underlying_shares":144048},"source":{"system":"sec-edgar","filing":"0001104659-18-002675","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1291937/000110465918002675/a4.xml","form_type":"4"}},{"id":4097703,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":36785,"kind":"person","name":"Bertrand William C JR","position":1,"cik":"0001291937","reported_name":"Bertrand William C JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2018-01-17T22:20:36.000Z","date":"2018-01-12","kind":"grant","acquired":true,"shares":644976,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP0.96 based on an exchange rate of $U.S. 1.3542 - GBP1.00.  The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable as to 161,244 Ordinary Shares on January 12, 2019 and will be exercisable as to the remainder in monthly installments of 13,437 Ordinary Shares on the twelfth of each month from February 12, 2019 through January 12, 2022."}],"balance_after":644976,"derivative":{"exercise_price":1.3,"expiration_date":"2028-01-12","underlying":"Ordinary Shares","underlying_shares":644976},"source":{"system":"sec-edgar","filing":"0001104659-18-002675","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1291937/000110465918002675/a4.xml","form_type":"4"}},{"id":4286937,"issuer":{"id":4972,"kind":"organization","name":"ARDELYX, INC."},"owners":[{"id":36785,"kind":"person","name":"Bertrand William C JR","position":1,"cik":"0001291937","reported_name":"Bertrand William C JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-06-09T23:05:54.000Z","date":"2017-06-07","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date."}],"balance_after":15000,"derivative":{"exercise_price":4.3,"expiration_date":"2027-06-07","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001140361-17-024618","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1437402/000114036117024618/doc1.xml","form_type":"4"}},{"id":4286936,"issuer":{"id":4972,"kind":"organization","name":"ARDELYX, INC."},"owners":[{"id":36785,"kind":"person","name":"Bertrand William C JR","position":1,"cik":"0001291937","reported_name":"Bertrand William C JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-06-09T23:05:54.000Z","date":"2017-06-07","kind":"grant","acquired":true,"shares":11627,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were issued pursuant to the Issuer's Non-Employee Director Compensation Program. The Reporting Person elected to receive stock in lieu of cash as permitted under the program."}],"balance_after":21481,"source":{"system":"sec-edgar","filing":"0001140361-17-024618","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1437402/000114036117024618/doc1.xml","form_type":"4"}}]}